drugset / Trial / NCT01006681
Vaccination Against Influenza H1N1 in Rheumatic Diseases
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The spread of Influenza H1N1 has prompted the development of vaccines against this virus. Immunocompromised patients are at increased risk of developing complications of Influenza H1N1. The efficacy and safety of H1N1 vaccination have not been evaluated in this population of patients.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Focetria | Vaccine | 7.5 ug | Intramuscular |
| Subject | Focetria | Vaccine | 7.5 mg | Intramuscular |